Lupin signs second partnership for its oncology pipeline, this time with German drug maker BI
BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially treat patients of skin and stomach cancer.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Germany Health | Partnerships | Pharmaceuticals | Skin